Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
J Orthop Res ; 2024 Apr 22.
Article in English | MEDLINE | ID: mdl-38650103

ABSTRACT

While it is well-established that early detection and initiation of treatment of developmental dysplasia of the hip (DDH) is crucial to successful clinical outcomes, research on the mechanics of the hip joint during healthy and pathological hip development in infants is limited. Quantification of mechanical behavior in both the healthy and dysplastic developing joints may provide insight into the causes of DDH and facilitate innovation in treatment options. In this study, subject-specific three-dimensional finite element models of two pigs were developed: one healthy pig and one pig with induced dysplasia in the right hindlimb. The objectives of this study were: (1) to characterize mechanical behavior in the acetabular articular cartilage during a normal walking cycle by analyzing six metrics: contact pressure, contact area, strain energy density, von Mises stress, principal stress, and principal strain; and (2) to quantify the effect on joint mechanics of three anatomic abnormalities previously identified as related to DDH: variation in acetabular coverage, morphological changes in the femoral head, and changes in the articular cartilage. All metrics, except the contact area, were elevated in the dysplastic joint. Morphological changes in the femoral head were determined to be the most significant factors in elevating contact pressure in the articular cartilage, while the effects of acetabular coverage and changes in the articular cartilage were less significant. The quantification of the pathomechanics of DDH in this study can help identify key mechanical factors that restore normal hip development and can lead to mechanics-driven treatment options.

2.
Sensors (Basel) ; 20(22)2020 Nov 19.
Article in English | MEDLINE | ID: mdl-33228249

ABSTRACT

A surface acoustic wave (SAW) sensor was investigated for its application in C-reactive protein (CRP) detection. Piezoelectric lithium niobate (LiNbO3) substrates were used to study their frequency response characteristics in a SAW sensor with a CRP sensing area. After the fabrication of the SAW sensor, the immobilization process was performed for CRP/anti-CRP interaction. The CRP/anti-CRP interaction can be detected as mass variations in the sensing area. These mass variations may produce changes in the amplitude of sensor response. It was clearly observed that a CRP concentration of 0.1 µg/mL can be detected in the proposed SAW sensor. A good fitting linear relationship between the detected insertion loss (amplitude) and the concentrations of CRP from 0.1 µg/mL to 1 mg/mL was obtained. The detected shifts in the amplitude of insertion loss in SAW sensors for different CRP concentrations may be useful in the diagnosis of risk of cardiovascular diseases.


Subject(s)
C-Reactive Protein , Cardiovascular Diseases , Sound , C-Reactive Protein/analysis , Cardiovascular Diseases/diagnosis
3.
Soft Matter ; 12(8): 2288-300, 2016 Feb 28.
Article in English | MEDLINE | ID: mdl-26781581

ABSTRACT

In this study, the influence of the functional groups by the diblock copolymers of poly(styrene-b-4-vinylpyridine) (PS-b-P4VP), poly(styrene-b-2-vinylpyridine) (PS-b-P2VP), and poly(styrene-b-methyl methacrylate) (PS-b-PMMA) on their blends with octa-functionalized phenol polyhedral oligomeric silsesquioxane (OP-POSS) nanoparticles (NPs) was investigated. The relative hydrogen bonding strengths in these blends follow the order PS-b-P4VP/OP-POSS > PS-b-P2VP/OP-POSS > PS-b-PMMA/OP-POSS based on the Kwei equation from differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopic analyses. Small-angle X-ray scattering and transmission electron microscopic analyses show that the morphologies of the self-assembly structures are strongly dependent on the hydrogen bonding strength at relatively higher OP-POSS content. The PS-b-P4VP/OP-POSS hybrid complex system with the strongest hydrogen bonds shows the order-order transition from lamellae to cylinders and finally to body-centered cubic spheres upon increasing OP-POSS content. However, PS-b-P2VP/OP-POSS and PS-b-PMMA/OP-POSS hybrid complex systems, having relatively weaker hydrogen bonds, transformed from lamellae to cylinder structures at lower OP-POSS content (<50 wt%), but formed disordered structures at relatively high OP-POSS contents (>50 wt%).

4.
Appl Radiat Isot ; 99: 117-21, 2015 May.
Article in English | MEDLINE | ID: mdl-25748057

ABSTRACT

OBJECTIVE: The present study relates to a method for preparing 188Re-labeled human serum albumin microspheres (HSAM) by 188Re(I)-tricarbonyl ion(188Re(OH2)3(CO)3)+). This radioactive particle can be subjected to radioembolization for liver tumor. METHODS: The particle sizes and conformations of HSA microspheres were analyzed by Particle sizes-Malvern mastersizer and Scanning Electron Microscope (SEM). For preparing 188Re(I)-tricarbonyl ion, the 188ReO4- was eluted from a 188W/188Re generator with saline. The radio labeling efficiency was analyzed with high-performance liquid chromatography (HPLC). Amino borane-reduced 188ReO4-was interacted with carbon oxide to form (188Re(OH2)3(CO)3]+). For preparing 188Re-HSA microspheres, the 188Re(I)-tricarbonyl ion was added into a vial with HSA microspheres. The in vitro stability was investigated. The rat was injected with 188Re-HSA microspheres via hepatic artery route. Nano-SPECT/CT Imaging was acquired after injection of 188Re-HSA microspheres. RESULTS: The shape of HSA microsphere was rough surfaced sphere or oval-shaped. The particle size was distributed between 20 and 35µm. In the RP-HPLC-UV chromatography, the yield of 188Re(I)-tricarbonyl ion was 75-80%. The labeling efficiency of 188Re-HSA microspheres in this method was more than 85%. After incubation, the 188Re(I)-tricarbonyl ion labeled HSA microspheres were found to be stable in vitro in normal saline and rat plasma. The result of Nano-SPECT/CT Imaging quantification analysis indicated that the percentage of injection dose %ID was maintained at 95% ID-88% ID from 2 to 72h after injection with 188Re- HSA microspheres. CONCLUSIONS: The method of 188Re(I)-tricarbonyl ion labeled HSA microspheres can proceed with high labeling yield. Furthermore, this method provided a convenient method for radio-labeling of HSA microspheres with 188Re as well as a kit for manufacturing.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/radiotherapy , Liver Neoplasms/metabolism , Liver Neoplasms/radiotherapy , Rhenium/therapeutic use , Serum Albumin/pharmacokinetics , Animals , Carcinoma, Hepatocellular/diagnostic imaging , Cell Line, Tumor , Contrast Media , Humans , Isotope Labeling/methods , Liver Neoplasms/diagnostic imaging , Male , Microspheres , Radioisotopes/therapeutic use , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Sprague-Dawley , Treatment Outcome
5.
Oncol Rep ; 28(5): 1736-42, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22922965

ABSTRACT

Liposomes are good candidates as drug carriers and have been widely investigated in drug delivery systems. In this study, a new combination of bimodal 188Re-(DXR)-liposome-BBN radiochemotherapeutics was designed and studied for treating solid pancreatic tumor by intravenous administration. The in vivo nuclear microSPECT/CT imaging of tumor targeting, prolonged survival time and therapeutic efficacy were evaluated in AR42J malignant pancreatic solid tumor-bearing nude mice. MicroSPECT/CT imaging of 188Re-liposome-BBN pointed to significant targeting in tumors at 24 h after intravenous injection (SUV=2.13 ± 0.98). Co-injection of a blocking dose of cold BBN (4 mg/kg) inhibited the accumulation of 188Re-liposome-BBN in tumors (SUV=1.82 ± 0.31). For therapeutic efficacy, inhibition of tumor growth in mice treated with 188Re-DXR-liposome-BBN was precisely controlled [mean growth inhibition rate (MGI) = 0.092] and had longer survival time [life-span (LS) = 86.96%] than those treated with anticancer drug 188Re-liposome-BBN (MGI = 0.130; LS = 75%), Lipo-Dox-BBN (MGI = 0.666; LS = 3.61%) and untreated control mice. An additive tumor regression effect was observed (CI 0.946) for co-delivery of 188Re-DXR-liposome-BBN radiochemotherapeutics. These results point to the potential benefit of the 188Re-(DXR)-liposome-BBN radiochemotherapeutics for adjuvant cancer treatment with applications in oncology.


Subject(s)
Bombesin/therapeutic use , Doxorubicin/therapeutic use , Pancreatic Neoplasms/therapy , Rhenium/therapeutic use , Administration, Intravenous , Animals , Bombesin/pharmacology , Cell Line, Tumor , Chemoradiotherapy , Doxorubicin/pharmacology , Humans , Mice , Multimodal Imaging , Organometallic Compounds/pharmacology , Organometallic Compounds/therapeutic use , Pancreatic Neoplasms/mortality , Positron-Emission Tomography , Radiopharmaceuticals/pharmacology , Radiopharmaceuticals/therapeutic use , Rhenium/chemistry , Rhenium/pharmacology , Tissue Distribution , Tomography, X-Ray Computed , Xenograft Model Antitumor Assays
6.
Oncol Rep ; 27(3): 678-84, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22109644

ABSTRACT

Liposomal doxorubicin (Lipo-DOX) has been widely and successfully used in chemotherapy for breast cancer patients. Since our previous studies found that 188Rhenium (188Re)-N,N-bis (2-mercaptoethyl)-N',N'-diethy-lethylenediamine (BMEDA)-labeled pegylated liposomes (188Re-liposomes) have radiotherapeutic potential in a colon cancer model, and little information is available to make a comparison of the therapeutic efficacy of internal radiotherapy and chemotherapy, this study evaluates the therapeutic efficacy of 188Re-liposomes and Lipo-DOX, in a 4T1 murine orthotopic breast cancer model. MicroSPECT/CT imaging showed that the highest uptake of 188Re-liposomes was found at 24 h after intravenous administration. The results of a bio-distribution assay also demonstrated that the highest uptake of 188Re-liposomes in a tumor was 3.03±0.29 (%ID/g) at 24 h, and that the highest tumor to muscle ratio was approximately 17 at 48 h. According to measurements of body weight and survival rate, the maximum tolerated doses (MTD) of 188Re-liposomes and Lipo-DOX were 37 MBq and 25 mg/kg, respectively. In a study of therapeutic efficacy, mice with 4T1 orthotopic breast tumors that were treated with 188Re-liposomes (4/5 MTD, 29.6 MBq) or Lipo-DOX (4/5 MTD, 20 mg/kg), showed a significant inhibition of tumor growth. In the small tumor model (50 mm3), the lifespan of 4T1 tumor-bearing mice treated with 188Re-liposomes and Lipo-DOX was increased by 21.7 and 169.6%, respectively, compared to those treated with normal saline. In the large tumor model (300 mm3), the lifespan of the 188Re-liposomes and the Lipo-DOX treated group was also increased by 35.2 and 141.2%, respectively. In this study, it was found that Lipo-DOX is better than 188Re-liposomes, for the treatment of 4T1 breast cancer. A further investigation of combined therapy, in a breast cancer model, using 188Re-liposomes and Lipo-Dox, to determine whether a synergistic effect exists, is ongoing in our laboratory.


Subject(s)
Doxorubicin/pharmacology , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/radiotherapy , Radioisotopes/administration & dosage , Rhenium/administration & dosage , Animals , Cell Line, Tumor , Combined Modality Therapy , Disease Models, Animal , Female , Injections, Intravenous/methods , Liposomes , Mammary Neoplasms, Experimental/metabolism , Mice , Mice, Inbred BALB C , Radioisotopes/pharmacokinetics , Rhenium/pharmacokinetics , Survival Rate , Tissue Distribution
7.
J Appl Toxicol ; 30(7): 680-7, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20981861

ABSTRACT

Liposomes can selectively target cancer sites and carry payloads, thereby improving diagnostic and therapeutic effectiveness and reducing toxicity. To evaluate therapeutic strategies, it is essential to use animal models reflecting important safety aspects before clinical application. The objective of this study was to investigate acute radiotoxicity of ¹88Re-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomes (¹88Re-BMEDA-liposome) in Sprague-Dawley rats. Rats were administered with ¹88Re-BMEDA-liposome, normal saline as blank or non-radioactive liposome as vehicle control via intravenous injection and observed for 14 days. Examinations were conducted with respect to mortality, clinical signs, food consumption, body weight and hematological and biochemical analyses. In addition, gross necropsy, histopathological examinations and cytogenetic analyses were also performed. None of the rats died and no clinical sign was observed during the 14-day study period. Rats administered with ¹88Re-BMEDA-liposome at dosage of 185 MBq displayed a significant weight loss compared with the control from study day (SD) 1 to SD 4, and the white blood cell count reduced to 5-10% of initial value (female: 18.55 ± 6.58 to 0.73 ± 0.26 x 10³ µl⁻¹; male: 14.52 ± 5.12 to 1.43 ± 0.54 x 10³ µl⁻¹) 7 days-post injection, but were found to have recovered on SD 15. There were no significant differences in biochemical parameters and histopathological assessments between the ¹88Re-BMEDA-liposome-treated and control groups. The frequencies of dicentric chromosomes were associated with dosage of ¹88Re-BMEDA-liposome. The information generated from this study on acute toxicity will serve as a safety reference for further subacute toxicity study in rats and human clinical trials.


Subject(s)
Rhenium/therapeutic use , Animals , Chelating Agents/administration & dosage , Chelating Agents/therapeutic use , Drug Evaluation, Preclinical , Ethylenediamines , Female , Injections, Intravenous , Liposomes/administration & dosage , Liposomes/chemistry , Male , Organometallic Compounds , Polyethylene Glycols/chemistry , Random Allocation , Rats , Rats, Sprague-Dawley , Rhenium/administration & dosage , Toxicity Tests, Acute/methods
8.
Nucl Med Biol ; 37(1): 95-104, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20122674

ABSTRACT

Nanocarriers can selectively target cancer sites and carry payloads, thereby improving diagnostic and therapeutic effectiveness and reducing toxicity. The objective of this study was to investigate the therapeutic efficacy of a new co-delivery radiochemotherapeutics of (188)Re-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomal doxorubicin (DXR) ((188)Re-DXR-liposome) in a C26 murine colon carcinoma solid tumor model. To evaluate the targeting and localization of (188)Re-DXR-liposome in C26 murine tumor-bearing mice, biodistribution, microSPECT/CT imaging and pharmacokinetic studies were performed. The antitumor effect of (188)Re-DXR-liposome was assessed by tumor growth inhibition, survival ratio and histopathological hematoxylin-eosin staining. The tumor target and localization of the nanoliposome delivery radiochemotherapeutics of (188)Re-DXR-liposome were demonstrated in the biodistribution, pharmacokinetics and in vivo nuclear imaging studies. In the study on therapeutic efficacy, the tumor-bearing mice treated with bimodality radiochemotherapeutics of (188)Re-DXR-liposome showed better mean tumor growth inhibition rate (MGI) and longer median survival time (MGI=0.048; 74 days) than those treated with radiotherapeutics of (188)Re-liposome (MGI=0.134; 60 days) and chemotherapeutics of Lipo-Dox (MGI=0.413; 38 days). The synergistic tumor regression effect was observed with the combination index (CI) exceeding 1 (CI=1.145) for co-delivery radiochemotherapeutics of (188)Re-DXR-liposome. Two (25%) of the mice treated with radiochemotherapeutics were completely cured after 120 days. The therapeutic efficacy of radiotherapeutics of (188)Re-liposome and the synergistic effect of the combination radiochemotherapeutics of (188)Re-DXR-liposome have been demonstrated in a C26 murine solid tumor animal model, which pointed to the potential benefit and promise of the co-delivery of nanoliposome radiochemotherapeutics for adjuvant cancer treatment on oncology applications.


Subject(s)
Colonic Neoplasms/diagnosis , Colonic Neoplasms/therapy , Doxorubicin/chemistry , Doxorubicin/therapeutic use , Radioisotopes/chemistry , Rhenium/chemistry , Animals , Autoradiography , Cell Line, Tumor , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Combined Modality Therapy , Disease Models, Animal , Doxorubicin/adverse effects , Doxorubicin/pharmacokinetics , Drug Stability , Drug Therapy , Injections, Intravenous , Male , Maximum Tolerated Dose , Mice , Radiotherapy , Survival Analysis , Tissue Distribution , Tomography, Emission-Computed, Single-Photon , Treatment Outcome , Tumor Burden/drug effects , Tumor Burden/radiation effects , X-Ray Microtomography
9.
Anticancer Res ; 30(1): 65-72, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20150618

ABSTRACT

Nanoliposome can be designed as a drug delivery carrier to improve the pharmacological and therapeutic properties of drug administration. (188)Re-labeled nanoliposomes are useful for diagnostic imaging as well as for targeted radionuclide therapy. In this study, the in vivo nuclear imaging, pharmacokinetics and biodistribution of administered nanoliposomes were investigated as drug and radionuclide carriers for targeting solid tumor via intravenous (i.v.) administration. The radiotherapeutics ((188)Re-liposome) and radiochemotherapeutics ((188)Re-DXR-liposome) were i.v. administered to nude mice bearing human HT-29 colorectal adenocarcinoma xenografts. (188)Re-liposome and (188)Re-DXR-liposomes show similar biodistribution profile; both have higher tumor uptake, higher blood retention time, and lower excretion rate than (188)Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylenediamine (BMEDA). In contrast to tumor uptake, the area under the curve (AUC) value of tumor for (188)Re-liposome and (188)Re-DXR-liposome was 16.5- and 11.5-fold higher than that of free (188)Re-BMEDA, respectively. Additionally, (188)Re-liposome and (188)Re-DXR-liposome had a higher tumor-to-muscle ratio at 24 h (14.4+/-2 .7 and 17.14+/-4.1, respectively) than (188)Re-BMEDA (1.6+/-0.1). The tumor targeting and distribution of (188)Re-(DXR)-liposome (representing (188)Re-DXR-liposome and (188)Re-liposome) can also be acquired by signal photon-emission computed tomography/computed tomography images as well as whole body autoradiograph. These results suggest that (188)Re-(DXR)-liposomes are potentially promising agents for passive targeting treatment of malignant disease.


Subject(s)
Adenocarcinoma/metabolism , Colorectal Neoplasms/metabolism , Doxorubicin/analogs & derivatives , Nanoparticles/administration & dosage , Radioisotopes/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Rhenium/pharmacokinetics , Adenocarcinoma/diagnostic imaging , Animals , Colorectal Neoplasms/diagnostic imaging , Doxorubicin/administration & dosage , Doxorubicin/pharmacokinetics , HT29 Cells , Humans , Liposomes/administration & dosage , Liposomes/pharmacokinetics , Mice , Mice, Nude , Organometallic Compounds/administration & dosage , Organometallic Compounds/pharmacokinetics , Radiopharmaceuticals/administration & dosage , Tissue Distribution , Tomography, Emission-Computed, Single-Photon/methods , Transplantation, Heterologous
10.
Anticancer Res ; 29(4): 987-94, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19414336

ABSTRACT

UNLABELLED: The activity of nuclear factor-kappaB (NF-kappaB), a nuclear transcription factor, influences both critical tumor promotion and host-tumor interactions. Preventing NF-kappaB activation may thus inhibit the development of cancer. Therefore, development of easy and rapid methods to evaluate the regulation of NF-kappaB is needed for drug discovery. The aim of this study was to visualize the regulation of NF-kappaB by real-time, noninvasive bioluminescence and microPET imaging in vivo. MATERIALS AND METHODS: A highly responsive HepG2/NF-kappaB/luc clone L for 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced tumor promotion inhibited by methotrexate (MTX) was selected by high-throughput bioluminescent imaging (BLI) in vitro. BLI and microPET using (18)F-fluorodeoxyglucose (FDG) imaging were performed in HepG2/NF-kappaB/Luc/L hepatoma-bearing SCID mice. RESULTS: The luciferase expression by BLI assay reflected that the TPA-induced NF-kappaB activity was suppressed by MTX after 16 h treatment. A positive correlation between in vitro and in vivo MTX-suppressed TPA-induced NF-kappaB activity was indicated. MicroPET imaging could not demonstrate any decrease in FDG uptake during the early stage at 24 h after TPA and MTX treatment. CONCLUSION: BLI directly revealed that MTX inhibited cellular transformation by suppressing NF-kappaB activity. Molecular imaging would accelerate the validation of the gene regulation of tumor cells in preclinical cellular and mouse models.


Subject(s)
Liver Neoplasms, Experimental/diagnostic imaging , Liver Neoplasms, Experimental/metabolism , Luminescent Measurements/methods , NF-kappa B/metabolism , Positron-Emission Tomography , Animals , Antimetabolites, Antineoplastic/pharmacology , Carcinogens/pharmacology , Diagnostic Imaging , Female , Fluorodeoxyglucose F18 , Humans , Liver Neoplasms, Experimental/drug therapy , Luciferases/genetics , Luciferases/metabolism , Methotrexate/pharmacology , Mice , Mice, Nude , Mice, SCID , Radiopharmaceuticals , Tetradecanoylphorbol Acetate/pharmacology , Tumor Cells, Cultured
11.
Nucl Med Biol ; 35(8): 883-93, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19026950

ABSTRACT

The pharmacokinetics and internal radionuclide therapy of intraperitoneally administrated (188)Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomal doxorubicin ((188)Re-DXR-liposome) were investigated in the C26 murine colon carcinoma ascites mouse model. After intraperitoneal administration of the nanotargeted bimodality (188)Re-DXR-liposome, the ascites and tumor accumulation of the radioactivity were observed, the levels of radioactivity within the ascites were maintained at relatively higher levels before 48 h and the levels of radioactivity in the tumor were maintained at steady levels after 4 h. The AUC((o-->infinity)) of (188)Re-DXR-liposome in blood, ascites and tumor was 9.3-, 4.2- and 4.7-fold larger than that of (188)Re-BMEDA, respectively. The maximum tolerated dose of intraperitoneally administrated (188)Re-DXR-liposome was determined in normal BALB/c mice. The survival, tumor and ascites inhibition of mice after (188)Re-DXR-liposome (22.2 MBq of (188)Re, 5 mg/kg of DXR) treatment were evaluated. Consequently, radiochemotherapeutics of (188)Re-DXR-liposome attained better survival time, tumor and ascites inhibition (decreased by 49% and 91% at 4 days after treatment; P<.05) in mice than radiotherapeutics of (188)Re-liposome or chemotherapeutics of Lipo-Dox did. Therefore, intraperitoneal administration of novel (188)Re-DXR-liposome could provide a benefit and promising strategy for delivery of passive nanotargeted bimodality radiochemotherapeutics in oncology applications.


Subject(s)
Ascites/therapy , Colonic Neoplasms/therapy , Doxorubicin/analogs & derivatives , Doxorubicin/administration & dosage , Polyethylene Glycols/therapeutic use , Radioisotopes/therapeutic use , Rhenium/therapeutic use , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed , Animals , Autoradiography , Colonic Neoplasms/diagnostic imaging , Doxorubicin/pharmacokinetics , Doxorubicin/therapeutic use , Drug Stability , Isotope Labeling , Male , Maximum Tolerated Dose , Mice , Mice, Inbred BALB C , Nanotechnology , Polyethylene Glycols/pharmacokinetics
12.
Anticancer Res ; 27(4B): 2217-25, 2007.
Article in English | MEDLINE | ID: mdl-17695506

ABSTRACT

Nanoliposomes are useful carriers in drug delivery. Radiolabeled nanoliposomes have potential applications in radiotherapy and diagnostic imaging. In this study, the biodistribution and pharmacokinetics of 188Re-BMEDA-labelled pegylated liposomes (RBLPL) and unencapsulated 188Re-BMEDA administered by the i.v. route in murine C26-colon tumour-bearing mice were investigated. MicroSPECT/CT images were performed to evaluate the distribution and tumor targeting of RBLPL in mice. For the biodistribution study, the highest uptake of liposome in tumors was 3.62% +/- 0.73% at 24 h after RBLPL administration, and the tumor to muscle ratio of RBLPL was 7.1-fold higher than that of 188Re-BMEDA. With image analysis, the highest SUV in tumor was 2.81 +/- 0.26 at 24 h after injection of RBLPL. The Pearson correlation analysis showed a positive correlation of tumor targeting or uptake of RBLPL between biodistribution and microSPECT semi-quantification imaging analysis (r = 0.633). The results of the pharmacokinetics revealed that the area under the tissue concentration-time curve (AUC) of RBLPL was 4.7-fold higher than that of unencapsulated 188Re-BMEDA. These results suggested the potential benefit and advantage of 188Re-labeled nanoliposomes for imaging and treatment of malignant diseases.


Subject(s)
Colonic Neoplasms/metabolism , Ethylenediamines/administration & dosage , Ethylenediamines/pharmacokinetics , Organometallic Compounds/administration & dosage , Organometallic Compounds/pharmacokinetics , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/pharmacokinetics , Animals , Cell Line, Tumor , Colonic Neoplasms/diagnostic imaging , Disease Models, Animal , Drug Stability , Ethylenediamines/chemistry , Isotope Labeling , Liposomes , Male , Mice , Mice, Inbred BALB C , Organometallic Compounds/chemistry , Radioisotopes , Radiopharmaceuticals/chemistry , Rhenium/chemistry , Tissue Distribution , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed
13.
Nucl Med Biol ; 34(4): 415-23, 2007 May.
Article in English | MEDLINE | ID: mdl-17499731

ABSTRACT

Nanoliposomes are important carriers capable of packaging drugs for various delivery applications through passive targeting tumor sites by enhanced permeability and retention effect. Radiolabeled liposomes have potential applications in radiotherapy and diagnostic imaging. The purpose of this study was to investigate the biodistribution, pharmacokinetics and imaging of nanotargeted (188)Re-N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-labeled pegylated liposomes (RBLPL) and unencapsulated (188)Re-BMEDA after intraperitoneal (ip) injection in a C26 colon carcinoma ascites mouse model. The nanopegylated liposomes were labeled with (188)Re-BMEDA. The labeling efficiency of RBLPL was 82.3+/-4.5%. In vitro stability of RBLPL in normal saline at room temperature and in rat plasma at 37 degrees C for 72 h was 92.01+/-1.31% and 82.4+/-1.64%, respectively. The biodistribution studies indicated that the radioactivity in ascites was 69.96+/-14.08 percentage injected dose per gram (% ID/g) at 1h to 5.99+/-1.97% ID/g at 48 h after ip administration of RBLPL. The levels of radioactivity in tumor were progressive accumulation to a maximum of 6.57+/-1.7% ID/g at 24 h. The radioactivity of (188)Re-BMEDA in ascites reached the maximum level of 54.89+/-5.91% ID/g at 1 h and declined rapidly with time. Pharmacokinetic studies revealed that the terminal half-life, total body clearance and area under the curve of RBLPL were 5.3-, 9.5- and 9.4-fold higher than that of (188)Re-BMEDA in blood, respectively. These results suggested that the long circulation, bioavailability and localization of RBLPL in tumor and ascites sites, which also demonstrate that the ip administration of RBLPL is a potential multifunctional nanoradiotherapeutics and imaging agents on a C26 colon carcinoma ascites mouse model.


Subject(s)
Colonic Neoplasms/diagnostic imaging , Ethylenediamines/pharmacokinetics , Organometallic Compounds/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Animals , Autoradiography , Drug Carriers , Ethylenediamines/chemical synthesis , Image Processing, Computer-Assisted , Injections, Intraperitoneal , Isotope Labeling , Liposomes , Male , Mice , Mice, Inbred BALB C , Neoplasm Transplantation , Organometallic Compounds/chemical synthesis , Polyethylene Glycols/chemistry , Radiopharmaceuticals/chemical synthesis , Tissue Distribution , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed
14.
Biochem Biophys Res Commun ; 341(2): 614-9, 2006 Mar 10.
Article in English | MEDLINE | ID: mdl-16427612

ABSTRACT

The transfer of sialic acids to the non-reducing terminal positions on sugar chains of glycoconjugates is catalyzed by sialyltransferases (STs). Increased sialylation is correlated with oncogenic transformation and metastatic potential. ST inhibitors may be potentially valuable as anti-cancer and anti-metastatic agents. In this study, we evaluated the effects of soyasaponin I (Ssa I), a known inhibitor of STs, on tumor metastasis through studying a highly metastatic cancer cell line B16F10. Ssa I specifically inhibited the expression of alpha2,3-linked sialic acids without affecting other glycans on the B16F10 cell surface. We also found that Ssa I decreased the migratory ability of cells, enhanced cell adhesion to extracellular matrix proteins. Finally, a pulmonary metastasis assay demonstrated that alteration of glycosylation in this way significantly reduced the ability of tumor cells to distribute to the lungs of mice. Collectively, these findings suggested that alpha2,3-linked sialic acids may play an important role in metastasis potential of B16F10 cells.


Subject(s)
Cell Membrane/metabolism , Glycine max/metabolism , N-Acetylneuraminic Acid/chemistry , Oleanolic Acid/analogs & derivatives , Saponins/pharmacology , Animals , Cell Adhesion , Cell Line, Tumor , Cell Movement , Extracellular Matrix/metabolism , Flow Cytometry , Glycosylation , Lung Neoplasms/secondary , Male , Melanoma, Experimental , Mice , Mice, Inbred C57BL , NIH 3T3 Cells , Neoplasm Invasiveness , Neoplasm Metastasis , Oleanolic Acid/pharmacology , Sialic Acids/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...